- EUDRACAP® colon targets the ileo-colonic region for oral drug delivery.
- It supports over 700 oral drug development programs using novel APIs.
- EUDRACAP® colon is produced under GMP for clinical and commercial use.
- Evonik's capsule platform is based on EUDRAGIT® polymers used globally.
Innovation in Drug Delivery
EUDRACAP® colon is a pioneering ready-to-fill capsule designed for targeted drug delivery to the ileo-colonic region. It facilitates the development of new oral drugs using novel active pharmaceutical ingredients (APIs), expediting the drug development process.
Applications and Impact
The capsule supports the safe and effective oral delivery of sensitive APIs, including live biotherapeutic products, RNA, and biologics. These are crucial for innovative treatments for conditions like obesity, HIV, Cystic Fibrosis, colorectal cancer, and infections.
Industry Recognition
Evonik's EUDRACAP® colon won the CPHI Excellence in Pharma Award in the "Finished Formulation" category, highlighting its role in advancing oral drug delivery solutions. The award was presented at the CPHI pharmaceutical trade show in Frankfurt.
Platform and Development
EUDRACAP® colon is part of Evonik's expanding platform of functional capsules, which includes EUDRACAP® enteric for upper small intestine drug release, EUDRACAP® Select for tailored CDMO services, and EUDRACAP® preclinic for early-stage development. The platform is built on EUDRAGIT® polymers, widely used in formulations across 80 countries and cited in over 23,000 patents.
